Exploring the mechanism of Shenqisherong pill against cervical spondylotic myelopathy by network pharmacology and molecular docking

Background Shenqisherong pill (SQSRP) has been used clinically to treat cervical spondylotic myelopathy (CSM) with satisfactory results; however, its active ingredients and mechanisms are unclear. The present study aimed explore the molecular of SQSRP against CSM using network pharmacology docking. Methods compounds in were obtained from public databases related literature, oral bioavailability (≥30%) drug-likeness (≥0.18) screened absorption, distribution, metabolism, excretion (ADME) criteria. Compounds-related CSM-related target genes identified databases, overlapping between a Venn diagram. Cytoscape STRING construct, visualize, analyze interaction these targets. Gene Ontology (GO) KEGG pathway enrichment analysis targets Omicshare tools constructed compound-overlapping network, target-pathway compound-target-pathway Cytoscape. Finally, docking software was verify Results A total 447 identified, ADME screening 96 as potentially ingredients. 249 compound-related 280 CSMrelated 53 identified. results compound protein-protein showed that pharmacological effects involved 56 genes. GO suggested therapeutic exerted by reducing inflammation, inhibiting apoptosis, protecting neurons. may be strongly associated PI3K-Akt, MAPK, IL-17, TNF, which might pivotal signaling pathways. Conclusions investigated pharmacology. findings proved could through multi-component, multitarget, multi-pathway synergy provide theoretical basis for subsequent extraction SQSRP.